Imdur Extended-Release Tablets

Confirm Imdur's Preventive Role First

Imdur is an oral extended-release tablet containing isosorbide mononitrate. Its defining role is the once-daily prevention of angina associated with coronary artery disease. It is not designed to stop chest pain that is already happening, so it should not be confused with a fast-acting medicine prescribed for an acute angina attack. This distinction is the most important starting point when comparing Imdur with nitroglycerin or with immediate-release isosorbide mononitrate products.

The extended-release form matters because it releases isosorbide mononitrate gradually rather than all at once. That supports a simpler daily routine but also means Imdur cannot replace an appropriate rapid-relief plan. New, severe, unusual, or persistent chest pain requires urgent medical assessment. Follow the emergency instructions provided by your prescriber, and call 911 when emergency help may be needed.

Imdur's Identity Among Nitrate Medicines

Imdur belongs to a group of medicines called nitrates. More specifically, it is a long-acting nitrate used to reduce the likelihood of angina episodes. The active ingredient is isosorbide mononitrate, and the concrete product form in our catalogue is an oral extended-release tablet in 20 mg, 30 mg, 40 mg, and 60 mg strengths.

These details distinguish Imdur from products containing isosorbide dinitrate, from immediate-release isosorbide mononitrate tablets, and from fast-acting forms of Nitroglycerin. They may all involve nitrate therapy, but they are not interchangeable. Their release patterns, dosing schedules, and intended roles differ. Readers comparing related cardiovascular treatments can also explore our Heart Disease and Blood Pressure categories.

Who May Discuss Imdur With a Prescriber?

Imdur is generally considered for adults with an established diagnosis of angina due to coronary artery disease when ongoing prevention is needed. It is not a product for self-diagnosing unexplained chest discomfort. A prescriber considers the diagnosis, current symptoms, blood pressure, other medicines, previous nitrate use, and the need for a reliable acute-relief plan before deciding whether an extended-release nitrate is appropriate.

Factors that can shape that discussion include:

• whether the goal is daily prevention rather than immediate relief of an attack;
• whether a once-daily extended-release routine is preferable to a medicine taken several times a day;
• whether the person already has instructions for using fast-acting nitroglycerin during an angina episode;
• whether dizziness, low blood pressure, or fainting has previously occurred with nitrates or other cardiovascular medicines;
• whether pregnancy, breastfeeding, or treatment of a child requires additional caution or evidence; and
• whether interacting medicines make nitrate therapy unsafe.

Safety and effectiveness in children have not been established. During pregnancy, use requires an individual assessment of potential benefit and fetal risk. Caution is also advised during breastfeeding because it is not known whether isosorbide mononitrate passes into human milk.

How Extended Release Supports Prevention

Isosorbide mononitrate relaxes blood vessels by increasing signalling related to nitric oxide in vascular smooth muscle. It mainly widens veins, which reduces the amount of blood returning to the heart and lowers the work the heart must perform. It can also widen arteries to some extent. Together, these effects reduce the heart muscle's demand for oxygen and help prevent the imbalance that produces angina symptoms.

The extended-release tablet releases the medicine gradually after the morning dose. It is designed to provide preventive activity during the day while allowing nitrate levels to fall later in the dosing interval. That lower-nitrate period is intentional because continuous exposure can lead to nitrate tolerance, meaning the medicine produces less effect over time. Taking extra doses or changing the schedule independently can disrupt this pattern and increase the risk of adverse effects.

A Consistent Once-Daily Routine

Imdur is normally taken once daily in the morning, according to the directions supplied with the prescription. Taking it at a consistent time helps preserve the intended daily pattern. The dose should not be increased, decreased, or rescheduled solely in response to symptoms without instructions from the prescriber managing the treatment.

Practical points for the routine include:

• Do not crush or chew an extended-release tablet, as doing so can interfere with controlled release.
• Swallow the tablet whole unless the directions for the specific supplied tablet expressly permit splitting.
• If a dose is missed, follow the instructions from the prescriber or pharmacist rather than doubling the next dose.
• Do not stop regular nitrate treatment abruptly without medical advice, particularly if angina symptoms are active.
• Keep a prescribed fast-acting angina medicine accessible and use it only according to the emergency plan provided to you.

Store the tablets at 25°C; temporary temperature excursions from 15°C to 30°C are permitted. Keep them in the packaging recommended for the product and out of the reach of children.

Which Strength and Package Quantity Match the Plan?

Our catalogue includes Imdur extended-release tablets in 20 mg, 30 mg, 40 mg, and 60 mg strengths. Available package quantities range from 30 to 360 tablets, but the exact quantities differ by strength. The correct choice is the strength and tablet count that match the current prescription and anticipated treatment period, not simply the option with the highest strength or largest quantity.

The strength should be treated as a clinical decision rather than a price-comparison variable. Two lower-strength tablets should not automatically be substituted for one higher-strength tablet, and a tablet should not be divided to create another dose unless the prescriber, pharmacist, and product directions confirm that this is appropriate. Extended-release products can differ in design even when they contain the same active ingredient.

Package quantity is a separate practical choice. A smaller quantity may be more suitable when a prescriber expects to reassess the regimen soon, while a larger quantity may reduce ordering frequency for a stable prescription. Before selecting a larger package, consider the prescribed daily quantity, expected follow-up, expiry information, and whether the dose is likely to change. Our displayed product options show which package quantities are available for each strength without implying that every quantity is offered in every strength.

What Benefits and Timing Are Reasonable to Expect?

Imdur is intended to reduce the frequency of angina episodes and improve the ability to carry out activities that would otherwise provoke symptoms. Its benefit is assessed through the pattern of symptoms over time, such as whether attacks happen less often, whether less rapid-relief medicine is needed, and whether ordinary activity becomes more manageable. It does not cure coronary artery disease, remove an arterial blockage, or replace other cardiovascular risk-reduction measures.

The medicine begins acting after a dose, but its success should not be judged by whether it stops active chest pain within minutes. It is an extended-release preventive treatment, not an acute rescue product. The prescriber may review symptom frequency, blood pressure, adverse effects, and use of fast-acting nitroglycerin when deciding whether the strength and routine remain suitable.

Headache is common when nitrate therapy begins and may lessen as the body adjusts. Dizziness, lightheadedness, flushing, weakness, or low blood pressure can also occur. A marked increase in symptoms, fainting, or chest pain that does not respond as directed requires prompt medical attention rather than an independent dose increase.

Safety Priorities Before Use

Imdur should not be used by anyone with a known hypersensitivity to isosorbide mononitrate, other nitrates, or relevant tablet ingredients. A history of very low blood pressure, fainting, recent cardiovascular events, or other significant heart or circulation problems should be reviewed before treatment. The prescriber also needs an accurate list of prescription medicines, non-prescription products, and recreational substances because some combinations with nitrates are dangerous.

Dizziness, visual disturbance, or low blood pressure may impair driving or operating machinery, particularly when treatment begins or the dose changes. Until the individual response is known, avoid activities in which sudden dizziness could cause harm. Standing up slowly can reduce lightheadedness, but persistent symptoms still need assessment.

The checklist below highlights product-specific information to confirm before use.

Interactions and Everyday Precautions

The most important interactions are those that can produce a severe fall in blood pressure. They should be addressed before the first dose rather than after symptoms occur:

• Erectile dysfunction medicines such as sildenafil, tadalafil, or vardenafil must not be combined with nitrates. Timing matters because some remain in the body longer than others, so a prescriber or pharmacist must advise when nitrate use is safe.
• Riociguat, used for certain forms of pulmonary hypertension, must not be combined with nitrate therapy because of the risk of serious hypotension.
• Alcohol can intensify dizziness, lightheadedness, and low blood pressure.
• Other blood-pressure-lowering medicines, including beta-blockers and calcium channel blockers, may be prescribed alongside Imdur, but their combined effects require clinical oversight.
• Other nitrate products can add to the blood-pressure-lowering effect. Fast-acting nitroglycerin may still be part of a planned angina regimen, but it must be used exactly as directed.

Tell every relevant health professional that you take a long-acting nitrate. This is especially important before a new medicine is prescribed or before treatment for erectile dysfunction or pulmonary hypertension is considered. Do not rely on spacing the medicines by a few hours unless a qualified professional has given product-specific instructions.

How Does Imdur Compare With Other Options?

The most useful comparison depends on the treatment goal. Imdur is a long-acting preventive option; it is not universally preferable to another nitrate or antianginal medicine. A prescriber may choose or combine treatments according to symptom pattern, heart rate, blood pressure, other conditions, adverse effects, and response to previous therapy.

Brand names do not by themselves establish equivalence. Before changing products, confirm the active ingredient, strength, dosage form, release type, route, and dosing directions. An immediate-release tablet should not be substituted for Imdur extended-release tablets without a new clinical plan.

Canadian Prescription and Product Records

Isosorbide mononitrate is a prescription medicine in Canada. Its regulatory status is separate from our ordering process and from the availability of a particular catalogue option. Available official records do not establish a current Canadian Drug Identification Number or marketed status for every listed Imdur strength and tablet formulation.

Health Canada's Drug Product Database is the official source for checking the Drug Identification Number, authorization status, product label, and manufacturer associated with a specific Canadian product. These details are worth confirming when the precise marketed product or manufacturer matters. Suspected adverse reactions can be reported to Health Canada through the Canada Vigilance Program.

A prescription decision should come from a prescriber who knows the person's diagnosis and current treatment. Online product information can support comparison and preparation, but it cannot determine whether unexplained chest pain is angina or whether a nitrate is safe for a particular person.

Ordering and Support From Our Team

We display Imdur in the supplied strengths and package quantities, with prices presented in Canadian dollars. When choosing an option, match the strength and quantity to the prescribed regimen and check the displayed selection carefully before completing the order. A larger package should not be used as a reason to continue an outdated dose after the treatment plan changes.

Our support team is available 24/7 by email, online chat, and phone for questions about the ordering process. A pharmacist is also available when a medicine-related question requires that level of support. These services have different purposes: our support team can help with an order, while a pharmacist can address questions about the product, its use, and relevant precautions. Urgent chest pain or another medical emergency should be directed to emergency services rather than an online support channel.

MedicalBrandNames has operated since 2017. We keep commercial claims separate from clinical decisions: our role is to present the available catalogue choices and support the ordering process, while the prescribed strength, dosing routine, and suitability of treatment remain matters for the patient and their health professionals.

A Focused Imdur Decision

Imdur is a relevant comparison when the goal is once-daily prevention of angina using an oral extended-release isosorbide mononitrate tablet. It is not the right product to rely on for immediate relief of chest pain, and it should not be substituted casually for an immediate-release nitrate, isosorbide dinitrate, or another antianginal medicine.

Before choosing a catalogue option, confirm five points: that Imdur's preventive role matches the treatment plan, that the selected strength is the prescribed one, that the package quantity is practical for the expected period of use, that no contraindicated interaction is present, and that an appropriate acute-angina plan is already understood. The 20 mg, 30 mg, 40 mg, and 60 mg options are choices within the same extended-release product identity, not steps to move through without clinical direction.

If those details are established, the remaining purchase decision is straightforward: select the strength and available package quantity that match the current regimen. If they are not established, resolve them with the prescriber or pharmacist before ordering rather than trying to infer the correct treatment from price, tablet count, or general product information.